Email This Release
Genzyme Reports Positive Top-Line Results of TOWER, a Pivotal Phase III Trial for AUBAGIOTM* (teriflunomide) in Relapsing Multiple Sclerosis
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words:
Terms of Use
|
© 2024 Business Wire